Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Spondylitis, Ankylosing
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more

Conditions: Pain
Interventions: Intravenous acetominophen, Ketorolac, intramuscular, Bupivacaine, subcutaneous, Normal saline; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Planet T1D; Behavioral
Lead sponsor: 3-C Institute for Social Development; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Arthroplasty, Replacement, Hip
Interventions: Standard Multimodal Analgesic Regimen with Opioid Prescription, Opioid-Reduced Multimodal Analgesic Regimen with Printed Prescription; Drug · Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions: Ibuprofen 600 mg, Education; Drug · Behavioral
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Eosinophilic Esophagitis
Interventions: EUR-1100, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 3 more

Conditions: Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions: Cyclosporin, Tacrolimus, 'Diabetes Education / Management'; Drug · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions: Liposomal Cyclosporine A, standard of care; Drug
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Conditions: Pain, Postoperative, Fracture, Ankle, Pilon Fracture of Tibia, Foot Fracture
Interventions: Auricular acupuncture; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions: Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 12
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more

Conditions: Medication Adherence, Transplant; Kidney
Interventions: mHealth Intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Postoperative
Interventions: Methadone Hydrochloride, Standard pain regimen, Spinal Fusion Surgery, Dexamethasone, Ketamine, Remifentanil, Sufentanil; Drug · Other · Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Ulcerative Colitis
Interventions: Hyperbaric Oxygen Therapy, Sham Hyperbaric Air; Device · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more

Conditions: HIV Infections
Interventions: Racivir, a non-nucleoside reverse transcriptase inhibitor; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 3
States / cities: Chicago, Illinois • The Bronx, New York • Columbia, South Carolina

Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, External Beam Radiation Therapy, Ganitumab, Ifosfamide, Stereotactic Radiosurgery, Therapeutic Surgical Procedure, Vincristine, Vincristine Sulfate; Drug · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 50 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 298
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more

Conditions: Covid-19 Prevention
Interventions: Ad26.COV2.S, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,085 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more

Conditions: Urinary Tract Infections
Interventions: LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX; Drug
Lead sponsor: Locus Biosciences; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Fresno, California • Lancaster, California • Los Angeles, California + 13 more

Conditions: Schizophrenia
Interventions: PF 03654746, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: TAK-755, Standard of care; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 0 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more

Conditions: Lung Transplant
Interventions: Cyclosporine Inhalation Solution (CIS); Drug
Lead sponsor: APT Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 15 more

Conditions: Functional Disorder of Intestine
Interventions: Docusate, Bowel medications; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: EDP-938, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 28 Days to 36 Months
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 12 more

Search by objective public record fields.

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Multimodal Pain Management for Cesarean Delivery

Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use

Optimizing Pain Control in Transurethral Resection of the Prostate

A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Auricular Acupuncture as Part of Multimodal Analgesia After Lower Leg Fracture

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients

Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

A Study of Ad26.COV2.S in Adults (COVID-19)

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Add On Treatment for Cognitive Deficits in Schizophrenia

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

Bowel Function After Minimally Invasive Urogynecologic Surgery

A Study to Evaluate EDP 938 Regimens in Children With RSV